XML 18 R8.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Operating activities    
Net income (loss) $ (302,843) $ 21,250
Adjustments to reconcile net income (loss) to net cash used in operating activities:    
Depreciation and amortization 18,975 7,632
Amortization of right-of-use assets and non-cash lease expense 5,671 2,590
Amortization of premiums and accretion of discounts on marketable securities 4,504 9,055
Stock-based compensation expense 92,985 36,010
Change in fair value of assumed common stock warrant liabilities   (168,674)
Impairment of fixed assets 7,806  
Other 474 223
Changes in operating assets and liabilities:    
Prepaid expenses and other assets 5,393 2,419
Accounts payable, accrued liabilities and accrued compensation 9,516 7,361
Other long term liabilities 2,100  
Operating lease liability 311 (1,168)
Net cash used in operating activities (155,108) (83,302)
Investing activities    
Purchases of property and equipment (121,004) (82,396)
Proceeds from maturities of marketable securities 634,390 611,005
Proceeds from sales of marketable securities 15,105 172,293
Purchases of marketable securities (402,247) (1,106,167)
Net cash (used in) provided by investing activities 126,244 (405,265)
Financing activities    
Proceeds from exercise of stock options and employee stock purchase plan 6,934 11,332
Proceeds from exercise of warrants   151,431
Payment of Business Combination share issuance costs   (1,016)
Proceeds from issuance of common stock, net of issuance costs paid   462,926
Proceeds from issuance of Class A Common Stock pursuant to Legacy QuantumScape Series F Preferred Stock Purchase Agreement, net of issuance costs   99,930
Principal payment for finance lease, net of credit (809) 5,210
Net cash provided by financing activities 6,125 729,813
Net increase (decrease) in cash, cash equivalents and restricted cash (22,739) 241,246
Cash, cash equivalents and restricted cash at beginning of period 338,223 115,410
Cash, cash equivalents and restricted cash at end of period 315,484 356,656
Supplemental disclosure of cash flow information    
Cash paid for interest 1,207 238
Purchases of property and equipment, not yet paid $ 13,828 21,724
Fair value of assumed common stock warrants exercised   $ 521,025